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Abstract
The COVID-19 pandemic caused by the SARS-CoV-2 virus has spread rapidly worldwide, leading to a
global outbreak. Most governments, enterprises, and scientific research institutions are participating in
the COVID-19 struggle to curb the spread of the pandemic. As a powerful tool against COVID-19,
artificial intelligence (AI) technologies are widely used in combating this pandemic. In this survey, we
investigate the main scope and contributions of AI in combating COVID-19 from the aspects of disease
detection and diagnosis, virology and pathogenesis, drug and vaccine development, and epidemic and
transmission prediction. In addition, we summarize the available data and resources that can be used for
AI-based COVID-19 research. Finally, the main challenges and potential directions of AI in fighting
against COVID-19 are discussed. Currently, AI mainly focuses on medical image inspection, genomics,
drug development, and transmission prediction, and thus AI still has great potential in this field. This
survey presents medical and AI researchers with a comprehensive view of the existing and potential
applications of AI technology in combating COVID-19 with the goal of inspiring researches to continue
to maximize the advantages of AI and big data to fight COVID-19.
1 Introduction
Severe Acute Respiratory Syndrome Corona-Virus 2 (SARS-CoV-2) is an emerging human infectious
coronavirus. Since December 2019, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 was
first reported in China and later in most of the countries in the world [10,59,220]. The World Health
Organization (WHO) announced on January 30, 2020, that the outbreak was a Public Health Emergency
of International Concern (PHEIC), and confirmed COVID-19 as a pandemic on March 11, 2020. As of
May 16, 2020, this disease has been reported in 216 countries or regions around the world and has
resulted in serious consequences including 4,525,497 confirmed COVID-19 cases and 307,395 deaths [216].
Most governments, enterprises, and scientific research institutions are fighting COVID-19 from all
aspects to curb the spread of the disease [49, 55, 58, 144]. Various stakeholders from different institutions
and backgrounds have provided abundant resources and capabilities to support this disease
battle [16,34,53,61,131,139,201]. The current scope of combating COVID-19 includes virology and
pathogenesis, disease diagnosis, epidemiology, therapeutics, and social control [95,236]. The virology,
origin and classification, physicochemical properties, receptor interactions, cell entry, genomic variation,
and ecology in terms of SARS-CoV-2 are thoroughly studied [7, 77,123,123,217,242]. Nucleic acid
testing, serologic diagnosis, and medical imaging (chest X-ray or CT imaging) are the main disease
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detection and diagnosis methods at present [30,83,106,198,227]. In terms of pathogenesis, topics such as
virus entry and spread, pathological findings, and immune response are the
focus [146,196,206,207,211,224]. In terms of epidemiology, extensive research has been conducted on the
source and spectrum of infection, clinical features, epidemiological characteristics, epidemic prediction,
and transmission route tracking [27, 115,221,222]. Potential therapeutics of COVID-19 include intensive
care, drug development, and vaccine development [36,118,150,200]. In addition, communication
prediction and social isolation are the current main social control methods [1, 99,157,203,235].
Artificial intelligence (AI) is defined as a technology that allows computers to imitate human
intelligence to process things, including Machine Learning (ML), knowledge graphs, natural language
processing, human-computer interaction, computer vision, biometrics, virtual reality, and augmented
reality [26,114,189]. As a subset of AI, ML is a type of algorithms that can automatically analyze and
obtain rules from data and use these rules for prediction or decision [156,228,229]. ML can be
subdivided into traditional ML and deep learning (DL). Traditional ML methods include logistic
regression, decision tree, random forest, K-nearest neighbor, Adaboost, K-means clustering, density
clustering, hidden Markov models, support vector machine, Naive Bayes, etc [22,125,142]. DL is a subset
of ML, and is a learning method for building deep structural models. Typical DL algorithms include
deep belief networks, convolutional neural networks, restricted Boltzmann machines, and recurrent
neural networks [66, 186]. In addition, ML techniques also include transfer learning, active learning, and
evolutionary learning. In recent years, AI technologies have achieved technical breakthroughs and are
widely used in various fields of intelligent medicine, including medical image inspection, disease-assisted
diagnosis, surgery, hospital management, and medical big data integration [189]. In addition, AI is
actively explored in emerging fields such as surgical robots, wearable devices, new drug discovery,
precision medicine, epidemics prevention and control, and gene sequencing.
Encouragingly, in the short period of time since the outbreak of COVID-19, research in the industry,
medical, and scientific fields has successfully used advanced AI technologies in the COVID-19 battle and
has achieved significant progress. For example, AI supports COVID-19 diagnosis through medical image
inspection and provides noninvasive detection solutions to prevent medical personnel from contracting
infections [4, 26,114]. AI is used in virology research to analyze the structure of SARS-CoV-2-related
proteins and predict new compounds that can be used for drug and vaccine development [23,136,243]. In
addition, AI has achieved virus source tracking through genomics research and successfully discovered
the relationships between SARS-CoV-2 and the bat virus, as well as SARS-CoV and the Middle East
respiratory syndrome-related coronavirus (MERS-CoV) [46,145,164]. Moreover, AI learns large-scale
COVID-19 case data and social media data to construct epidemic transmission models to accurately
predict the time of disease outbreak, transmission route, transmission range, and
impact [116,147,152,171]. AI is also widely used in epidemic prevention and social control, such as
airport security inspections, patient trajectory tracking, and epidemic visualization [163,163].
In this survey, we present a comprehensive view of the landscape and contributions of AI in
combating COVID-19. The main scope of AI in COVID-19 research includes the aspects of disease
detection and diagnosis, virology and pathogenesis, drug and vaccine development, and epidemic and
transmission prediction. Note that due to the rapid development of the COVID-19 epidemic, we cited
many preprinted references for a comprehensive investigation, where these references still need to be
assessed on their accuracy and quality through peer review. The main scope of AI in combating
COVID-19 is summarized in Fig. 1.
The rest of the paper is structured as follows. Sections 2 to 5 discuss the four main scope of AI against
COVID-19. Section 6 summarizes the available data and resources to support COVID-19 research.
Section 7 highlights the challenges and potential directions in this field. Finally, Section 8 presents the
conclusion. Table 1 gives the abbreviations and descriptions of the AI methods used in this survey.
2 Disease Detection and Diagnosis
Diagnosis of virus infection is an important part of COVID-19 research. The current detection and
diagnosis methods for SARS-CoV-2 virus and COVID-19 disease mainly include nucleic acid testing,
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Figure 1. Main scope of AI in fighting against COVID-19. We collected 1273 online publications related
to COVID-19, SARS-CoV-2, and 2019-nCoV from databases such as Nature, Elsevier, Google Scholar,
arxiv, biorxiv, and medRxiv. Then, we filter out 267 papers that explicitly use AI methods.
Table 1. Abbreviations and descriptions of the AI methods used in this survey.
Abbreviation Description Abbreviation Description
CL Chaotic learning MAE Modified auto-encoder
CNN Convolutional neural network MLP Multi-layered perceptron
DCNN Deep CNN Mol2Vec Molecular to vectors
DNN Deep neural network R-CNN Regional convolutional network
DT Decision tree PNN Polynomial neural networks [141]
FCN Fully convolutional network PR Polynomial regression [44]
GA Genetic algorithm RF Random forest [22]
GAE Generative auto-encoder RL Reinforcement learning
GANs Generative adversarial nets RNN Recurrent neural network
GAN Generative adversarial network SVM Support vector machine
GRU Gate recurrent unit SVR Support vector regression [13]
KNN K-nearest neighbor TL Transfer learning
LR Logistic regression t-SNE t-distributed stochastic neighbor
embedding [125]
LSTM Long short-term memory [66] VAE Variational auto-encoder [186]
serological diagnosis, chest X-ray and CT image inspection, and other noninvasive methods.
2.1 RT-PCR Detection
Benefitting from the advantages of high sensitivity and specificity, real-time Reverse Transcriptase
Polymerase Chain Reaction (RT-PCR) is the current standard detection technology in diagnosing the
SARS-CoV-2 virus and bacterial infections. Using RT-PCR, 9 RNA positives were detected from
pharyngeal swabs of patients, indicating that the SARS-CoV-2 virus had spread in communities of
Wuhan, China, in early January 2020 [106]. The shedding of the SARS-CoV-2 virus detected in the
throat, lungs, and feces suggests multiple routes of virus transmission [217,227]. However, RT-PCR faces
the limitations of a complicated sample preparation, low detection efficiency, and high false-negative
rate [106,212,223].
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Isothermal nucleic acid amplification and blood testing methods are also commonly used for the rapid
screening of SARS-CoV-2 [103,122,223]. An ML classification method was used for blood testing to
extract important routine hematological and biochemical characteristics and to provide COVID-19
classification. In [223], 105 blood test reports were collected, of which, 27 were collected as positive
saples from patients with confirmed COVID-19, and for comparison, negative samples were collected
from patients with ordinary pneumonia, tuberculosis, and lung cancer. Each sample contains 49 feature
variables, including routine hematological and biochemical parameters. Next, the authors implemented
the RF algorithm [22] on the training samples to perform feature learning and classification. Based on
the extracted 11 key feature variables, they built an RF classifier and tested 253 samples of 169 patients
with suspected COVID-19 with an accuracy of 96.97%. Although AI technologies rarely participate
directly in RT-PCR and blood testing, the viral load and COVID-19 case data collected in these
methods provide important data sources for the subsequent AI-based analysis.
2.2 Medical Image Inspection
Medical imaging inspection is another widely used clinical approach for COVID-19 detection and
diagnosis. COVID-19 medical image inspection mainly includes chest X-ray and lung CT imaging. AI
technology plays an important role in medical image inspection and has achieved significant results in
image acquisition, organ recognition, infection region segmentation, and disease classification. It not only
greatly shortens the time of a radiologist’s image diagnosis but also improves the accuracy and
performance of the diagnosis. We will discuss in detail the contributions of AI methods to chest X-ray
and lung CT imaging.
2.2.1 CT Image Inspection
CT imaging provides an important basis for the early diagnosis of COVID-19. The CT imaging
manifestations of COVID-19 are mainly Ground Glass Opacity (GGO) in the periphery of the subpleural
region, and some are consolidated. If the situation improves, the area will be absorbed and form fibrous
stripes. Examples of lung CT images of normal and COVID-19 cases are shown in Fig. 2 [42,161,184].
Figure 2. Examples of lung CT images of normal and COVID-19 cases.
The progress of CT image inspection based on AI usually includes the following steps: Region Of
Interest (ROI) segmentation, lung tissue feature extraction, candidate infection region detection, and
COVID-19 classification. The representative AI architecture for COVID-19 CT image classification is
shown in Fig. 3.
The segmentation of lung organs and ROIs is a foundational step in AI-based image inspection. It
depicts the ROIs in lung CT images (such as lungs, lung lobes, bronchopulmonary segments, and
infected regions or lesions) for further evaluation and quantification. Different DL models (such as
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Figure 3. Representative architecture of AI-based CT image classification and COVID-19 inspection.
U-Net, V-Net, and VB-Net) have been used for CT image segmentation [32,94,114,193,226]. In [179],
Shan et al. collected 549 CT images from patients with confirmed COVID-19 and proposed an improved
segmentation model (named VB-NET) based on the V-NET [117] and ResNet [69] models. In [32], Chen
et al. built a DL model based on the U-Net++ structure [244] to extract the ROIs from each CT image
and detect the training curve of suspicious lesions. In [226], Xu et al. used a 3D DL model to segment
the infection regions from lung CT images. They then built a classification model using ResNet and
location-attention structures and divided the segmented area images into three categories, such as
COVID-19, influenza-A viral pneumonia, and normal. In [114], Li et al. used the U-Net segmentation
model to extract the lung organ from each lung CT image as an ROI. In [94], Jin et al. proposed an
AI-based COVID-19 diagnostic system, which consists of a lung segmentation module and a COVID-19
diagnostic module. The lung segmentation module is implemented based on Deeplabv1 [33]. In [193],
Tang et al. used the VB-Net model [179] to accurately segment 18 lung regions and infected regions from
lung CT images and further calculated 63 quantitative features.
Focusing on the detection and localization of candidate infection regions, different AI methods were
proposed in [65, 85, 181,212]. In [65], Gozes et al. used commercial software to identify lung nodules and
small opacities within the 3D lung volume. Then, they constructed a DL model consisting of U-Net and
ResNet structures, where the U-Net module was used to extract the ROI regions, and the ReseNet model
was used to detect and classify diffuse turbidity and ground glass infiltration. The authors compared the
CT images of 56 patients with confirmed COVID-19 and 101 noncoronavirus patients and analyzed the
CT features of COVID-19 in detail. In [181], Shi et al. used a CNN model based on V-Net to segment
lung organs and infection regions from lung CT images. Then, they used the LASSO method to
calculate the best CT morphological features. Finally, the severity of COVID-19 was predicted and
evaluated based on the best CT morphology and clinical features. In [212], Wang et al. collected 195 CT
images from 44 patients with COVID-19 and 258 CT images from 55 negative patients. They used the
CNN model with the Inception structure [191] to classify randomly selected ROI images and predict
COVID-19 disease. In [85], Huang et al. used an InferReadTM CT pneumonia tool based on AI to
quantitatively evaluate changes in the lung burden of patients with COVID-19. The tool includes three
modules: lung and lobe region extraction, pneumonia segmentation, and quantitative analysis. The CT
image features of COVID-19 pneumonia are divided into four types: mild, moderate, severe, and critical.
Based on ROI segmentation and candidate infection region detection, the important features of ROIs
and infection regions are extracted for COVID-19 classification [156]. In [156], Qi et al. collected 71 CT
images from 52 patients with confirmed COVID-19 in 5 hospitals. They used the pyradiomics method to
extract 1,218 features from each CT image and then performed LR and RF methods on these features to
distinguish between short-term and long-term hospital stay. In [180], Shi et al. used the VB-NET
model [179] to segment the infection and lung fields from CT images and divided them based on 96
features, including 26 volume features, 31 digital features, 32 histogram features, and 7 surface features.
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Next, they proposed an iSARF method to classify features and predict COVID-19 disease. Comparative
experiments showed that the iSARF method is superior to the LR, SVM, and NN methods. In [241],
Zheng et al. proposed a 3D DCNN model (named DeCoVNet) to detect COVID-19 from CT images.
The proposed DeCoVNet model includes three components. The first component uses vanilla 3D
convolutional layers to extract lung image features, the second component consists of two 3D residual
blocks that perform element conversion on the 3D feature maps, and the third component gradually
extracts the information in the 3D feature map through 3D max-pooling and outputs the probability of
COVID-19. In [187], Song et al. collected 1990 CT images, including 777 images from 88 patients with
COVID-19, 505 images from 100 patients with bacterial pneumonia, and 708 images from 86 healthy
people. They proposed a DRE-NET DL model based on the pretrained ResNet50 structure and
functional pyramid networks. DRE-NET extracts the top-K lesion features from each CT image to
predict the classification of patients with COVID-19.
The lack of large-scale datasets is the main challenge that hinders the implementation of AI-based
CT image inspection and affects diagnostic performance. To address these challenges, strategies such as
transfer learning, data augmentation, and “Human-In-The-Loop” were used in [94, 179,239]. In [94], Jin
et al. used the ImageNet7 dataset [47] to pretrain the proposed 2D classification network. In [239], Zhao
et al. provided a public COVID-19 CT scan dataset, including 275 COVID-19 cases and 195
non-COVID-19 cases. They used data augmentation and TL methods to alleviate the shortage of
training data. In terms of data augmentation, they used transformation operations to expand the
training dataset, such as random transformation, cropping, and rotation. In terms of TL, they
pretrained the DenseNet model [84] on the chest X-ray dataset [213] and then used the pretrained model
to predict COVID-19. In addition, a “Human-In-The-Loop” strategy was adopted to reduce the
workload of radiologists in annotating the training samples [179]. Radiologists annotate a small portion
of training samples in the first batch of training. Then, they manually correct the segmentation results
in the second batch and used them as annotations of the images. Iterative training is performed in this
way to complete the annotation of all training samples.
It is commendable that several works provided open-source code of the designed models and online
COVID-19 CT image inspection systems. For example, Li [114], Jin [94], Zheng [241], and Zhao [239]
published the proposed DL models on GitHub [88]. In addition, Song et al. [187] provided an online CT
diagnosis service. Wang et al. [212] provided a public website for CT image uploading and testing.
In [32], Chen et al. developed a public online CT diagnostic system, and anyone can upload CT images
for self-diagnosis. More detailed information about AI-based CT image segmentation and classification
methods is provided in Table 2 and Fig. 4.
2.2.2 Chest X-ray Image Inspection
Compared with CT images, chest X-ray (CXR) images are easier to obtain in clinical radiology
inspections. Although CXR image inspection is a typical imaging method used for COVID-19 diagnosis,
it is generally considered to be less sensitive than CT image inspection. Some CXR images of patients
with early COVID-19 showed normal characteristics. The radiological signs of COVID-19 CXR images
include airspace opacity, GGO, and later mergers. In addition, the distribution of bilateral, peripheral,
and lower regions is mostly observed. Examples of CXR images of normal and COVID-19 cases are
shown in Fig. 5 from [124,160]. The CXR image inspection process based on AI techniques usually
includes steps such as data preprocessing, DL model training, and COVID-19 classification. The
representative AI architecture for COVID-19 CXR image inspection is shown in Fig. 6.
Unlike CT images, CXR image segmentation is more challenging because the ribs are projected onto
soft tissues, which is confused with image contrast. In this way, most DL models focus on the
classification of the entire CXR image, while few works focus on segmenting ROIs and lung organs from
CXR images. In [67], Hassanien et al. used a classification method to identify and classify COVID-19 on
lung X-ray images through a multilevel threshold and SVM. A multilevel image segmentation threshold
was used to segment the lung organs from the background, and then the SVM module classified the
infected lungs from the uninfected lungs.
Focusing on COVID-19 classification based on CXR images, several studies built AI-based
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Table 2. AI-based CT image segmentation and classification methods for COVID-19 inspection.
Literature Data
sources
Data
size
COVID-19
cases
AI methods ACC/AUC Sensitivity Specificity
Chen [32] 1 private 35,355 20,886 U-Net++ 95.24% 100% 94.0%
Gozes [65] private 157 56 U-Net, ResNet 99.6% 98.2% 92.2%
Huang [85] private 842 842 U-Net - - -
Jin [94] 2 [11, 48] 2095 970 Deeplab, ResNet 94.98% 94.06% 95.47%
Li [114] 3 private 4,356 1,325 U-Net, ResNet 96.0% 90.0% 96.0%
Qi [156] private 52 52 LR, RF 97.0% 100% 75.0%
Shan [179] private 549 549 V-Net, ResNet - - -
Shi [180] private 2685 1658 RF 87.9% 90.7% 83.3%
Shi [181] private 196 196 V-Net 89.0% 82.2% 82.8%
Song [187] 4 private 1990 777 DRE-Net 94.0% 93.0% -
Tang [193] private 176 176 RF 87.5% - -
Wang [212] 5 private 453 195 Inception 73.1% 74.0% 67.0%
Xu [226] private 618 219 ResNet 86.7% - -
Zhao [239] 6 [239] 470 275 DenseNet 84.7% 76.2% -
Zheng [241] 7 private 630 630 DeCoVNet 90.1% 90.7% 91.1%
1
http://121.40.75.149/znyx-ncov/index.
2
https://github.com/ChenWWWeixiang/diagnosis covid19.
3
https://github.com/bkong999/COVNet.git.
4
http://biomed.nscc-gz.cn/server/Ncov2019.
5
https://ai.nscc-tj.cn/thai/deploy/public/pneumonia ct.
6
https://github.com/UCSD-AI4H/COVID-CT.
7
https://github.com/sydney0zq/covid-19-detection.
Figure 4. Relationship between AI methods and applications of COVID-19 CT image inspection.
classification models by nesting or combining existing ML and DL models. In [73], Hemdan et al.
proposed a DL framework (called COVIDX-Net) to help radiologists automatically diagnose COVID-19
based on CXR images. The proposed framework integrates 7 DCNN models with different structures,
such as VGG19 [183], DenseNet201 [84], ResNetV2 [29], InceptionV3, InceptionResNetV2 [189],
Xception [39], and MobileNetV2 [170]. Each model was separately trained on CXR images to classify the
patient’s status as COVID-19 positive or negative. In [178], Sethy et al. used different DCNN models in
an SVM classifier to diagnose COVID-19 on CXR images. Eleven DCNN models were used as image
feature extractors, such as AlexNet, GoogleNet, DenseNet, Inception, ResNet, VGG, XceptionNet, and
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Figure 5. Examples of chest X-ray images of normal and COVID-19 cases.
Figure 6. Representative architecture of AI-based CXR image classification and COVID-19 inspection.
InceptionResNet. Then, an SVM classifier was used to classify the extracted image features to determine
whether the input image was COVID-19. In [26], Castiglioni et al. collected CXR data (610 images,
including 324 COVID-19 cases) from Lombardy, Italy, and constructed a DCNN model to predict
COVID-19 disease. The DCNN model is equipped with 10 CNN models, each of which uses the
ResNet-50 structure and has been pretrained on the ImageNet dataset. Ioannis et al. [9] evaluated the
performance of 5 DCNN models recommended for medical image classification, including VGG19,
MobileNetV2, Inception, Xception, and InceptionResNetV2. To address the shortcomings of the
small-scale COVID-19 dataset, each model was pretrained on the ImageNet dataset by using the TL
strategy. Then, each pretrained model was executed on the CXR dataset. In [137], Narin et al. also used
3 typical DCNN models (ResNet50, InceptionV3, and InceptionResNetV2) to classify COVID-19 from a
small-scale CXR dataset (100 images, including 50 COVID-19 cases).
Another group of works constructed specific DL models for COVID-19 classification [237]. For
example, Zhang et al. [237] proposed a new DL model, which consists of a backbone network, a
classification module, and an anomaly detection module. The backbone network extracts the features of
each input CXR image. The classification module and anomaly detection module use the extracted
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features to generate classification scores and scalar anomaly scores, respectively. In [209], Wang et al.
introduced a COVID-Net DCNN model to identify COVID-19 cases based on CXR images. The
COVID-Net model uses a large number of convolutional layers in a projection-expansion-projection
design pattern. They collected 13,800 CXR images from 13,725 patients (including 183 COVID-19
patients) to establish a CXR database (called COVIDx) for training COVID-Net. It is commendable
that the authors provided an open-source of the proposed model code and the COVIDx database.
Similar to CT images, in CXR image inspection, there is also the problem of a lack of large-scale
datasets for DL model training. In [121], Loey et al. used the GAN model [86] to generate more CXR
images, thereby extending the scale of the CXR dataset. In addition, three DL models (Alexnet [109],
GoogleNet [190], and ResNet18 [69]) were used to classify CXR images into four categories: COVID-19,
normal, pneumonia bacteria, and pneumonia virus. In [127], Maghdid et al. used CNN and AlexNet
models to train CXR and CT images to diagnose COVID-19 cases, respectively. Among them, the
AlexNet model was pretrained on the ImageNet dataset to perform COVID-19 classification on the
datasets in [41, 124,140]. Unlike existing TL and image augmentation methods, Afshar et al. designed a
capsule network model (named COVID-CAPS) suitable for small-scale CXR datasets [2]. Each layer of
the COVID-CAPS model contains multiple capsules, and each capsule represents a specific image
instance at a specific position through multiple neurons. The capsule module [75] uses protocol routing
to capture alternative models of spatial information and attempts to reach a consensus on the existence
of objects. In this way, the protocol uses information from instances and objects to identify the
relationship between them without the need for large-scale datasets. More detailed information about
AI-based CXR image classification methods for COVID-19 inspection is shown in Table 3 and Fig. 7.
Table 3. AI-based CXR image classification methods for COVID-19 inspection.
Literature Data sources Data
size
COVID-19
cases
AI methods Accuracy
Afshar [2] 2 [41, 138] 100 50 COVID-CAPS 95.7%
Castiglioni [26] private 610 324 ResNet 89.0%
Ioannis [9] [41,102,112] 1427 224 VGG, MobileNet, Inception, Xception, In-
ceptionResNet
96.78%
Hassanien [67] private 40 25 SVM 97.48%
Hemdan [73] [41,159] 50 25 VGG, DenseNet, ResNet, Inception, In-
ceptionResNet, Xception, MobileNet
80.0%
Loey [121] [41, 138] 306 69 Alexnet, GoogleNet, ResNet 80.6%
Maghdid [127] [41,124,140] 170 60 CNN, AlexNet 94.0%
Narin [137] [41, 138] 100 50 ResNet, Inception, InceptionResNet 98.0%
Sethy [178] [41,138] 50 25 AlexNet, DenseNet, GoogleNet, Inception,
ResNet, VGG, Xception, InceptionResNet,
SVM
95.38%
Wang [209] 1 [24, 41,138] 13,800 183 COVID-Net 92.6%
Zhang [237] [41, 213] 1531 100 new DL 96.0%
1
https://github.com/lindawangg/COVID-Net.
2
https://github.com/ShahinSHH/COVID-CAPS.
2.3 Other Detection Technologies
In addition to RT-PCR detection and image inspection techniques, some noninvasive measurement
methods have also been used for COVID-19 detection and diagnosis, including cough sound judgment
and breathing pattern detection.
(1) Monitoring COVID-19 through AI-based cough sound analysis.
Schuller et al. [174] discussed the potential application of computer audition (CA) and AI in the
analysis of cough sounds in patients with COVID-19. They first analyzed the CA’s ability to
automatically recognize and monitor speech and cough under different semantics, such as breathing, dry
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Figure 7. Relationship among CXR datasets, AI methods, and applications of CXR image inspection.
and wet coughing or sneezing, speech during colds, eating behaviors, drowsiness, or pain. Then, they
suggested applying the CA technology to the diagnosis and treatment of patients with COVID-19.
However, due to the lack of available datasets and annotation information, there is no report on the
application of this technology in COVID-19 diagnosis. Similarly, Iqbal et al. [90] also discussed an
abstract framework that uses the speech recognition function of mobile applications to capture and
analyze the cough sounds of suspicious persons to determine whether the user is healthy or suffers from a
respiratory disease. In [214], Wang et al. analyzed the respiratory patterns of patients with COVID-19
and other breathing patterns of patients with influenza and the common-cold. In addition, they
proposed a respiratory simulation model (named BI-AT-GRU) for COVID-19 diagnosis. The
BI-AT-GRU model includes a GRU neural network with a bidirectional and attention mechanism and
can classify 6 types of clinical respiratory patterns, such as Eupnea, Tachypnea, Bradypnea, Biots,
Cheyne-Stokes, and Central-Apnea.
(2) COVID-19 diagnosis based on noninvasive measurements.
In [128], Maghdid et al. designed an abstract framework for COVID-19 diagnosis based on smart
phone sensors. In the proposed framework, smart phones can be used to collect the disease
characteristics of potential patients. For example, the sensors can acquire the patient’s voice through the
recording function and can obtain the patient’s body temperature through the fingerprint recognition
function. Then, the collected data are submitted to the AI-supported cloud server for disease diagnosis
and analysis.
3 Virology and Pathogenesis
The virology and pathogenesis of SARS-CoV-2 are one of the most important scientific studies in the
fields of biology and medicine. Scientists have analyzed the virus characteristics of SARS-CoV-2 through
proteomics and genomic studies [7, 77,123]. In the field of virology, the origin and classification of
SARS-CoV-2, the physical and chemical properties, receptor interactions, cell entry, and the ecology and
genomic variation in SARS-CoV-2 have been studied [123,217,242]. We mainly discuss the contribution
of AI in the pathological research of SARS-CoV-2 from the perspective of proteomics and genomics.
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3.1 Proteomics
Since the advent of SARS-CoV-2, there have been a large number of research achievements in proteomics.
Five types of structural proteins of SARS-CoV-2 were confirmed, including nucleocapsid (N) proteins,
envelope (E) proteins, membrane (M) proteins, and spike (S) proteins [145,206,240]. In addition, other
proteins translated in the host cells essential for virus replication have also attracted the attention of
researchers, such as non-structural protein 5 (NSP5) and 3C-like protease (3CLpro). Moreover, several
studies have shown that SARS-CoV-2 uses the human Angiotensin-Converting Enzyme 2 (ACE2) to
enter the host [77,242]. In this field, AI techniques are used to predict protein structures and analyze the
interaction network between proteins and drugs. The representative AI architecture for protein structure
predication is shown in Fig. 8.
Figure 8. Representative AI architecture for protein structure predication.
In [176,177], Senior et al. used DL models to implement the AlphaFold system for protein structure
prediction. The AlphaFold system uses a ResNet model [69] to analyze the covariance and amino acid
residue contacts in homologous gene sequences and to predict the corresponding protein structures. The
AlphaFold system consists of a feature extraction module and a distance prediction neural network. The
feature extraction module is responsible for searching for protein sequences that are similar to the input
protein sequences and constructing the multiple sequence alignment (MSA). The module simultaneously
generates residual position and sequence contour features, and the output of 485 feature parameters are
input into the distance prediction neural network. The distance prediction neural network is a
two-dimensional (2D) ResNet structure, which is responsible for accurately predicting the distance
between all residue pairs of every two protein sequences. The authors added a one-dimensional output
layer to the network to predict the accessible surface area, distance map, and secondary structure of each
residue. Finally, the generated potential is optimized by gradient descent to generate protein structures.
Based on [176,177], Jumper et al. [96] used the AlphaFold system to predict the structure of
SARS-CoV-2 membrane proteins. They published the predicted protein structures such as 3a, Nsp2,
Nsp4, Nsp6, and papain-like proteases. Although the structure of these proteins has not been verified by
clinical experiments, this publication allows researchers to quickly conduct SARA-CoV-2 studies.
In [145], Ortega et al. used a computational method to detect changes in the S1 subunit of the spike
receptor-binding domain and determined mutations in the SARS-CoV-2 spike protein sequence, which
may be beneficial for studying human-to-human transmission. They collected sequences for modeling
and constructed the SARS-CoV-2 spike protein model from the Protein Data Bank (PDB) [19] and used
SWISS-MODEL software [12] to construct the SARS-CoV-2 spike protein model. Then, Z-dock
software [151] was used to dock between the spike protein and ACE2, and a clustering algorithm was
used to cluster the docking results. The work indicated that the SARS-CoV-2 spike protein has a higher
affinity for human ACE2 receptors.
Another branch of AI-assisted proteomics research involves finding new compounds and drug
candidates for the treatment of COVID-19 by building interactive networks and knowledge maps
between proteins and drugs. Please see Section 4 for details.
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3.2 Genomics
Genomics is mainly used in SARS-CoV-2 to analyze the origin of SARS-CoV-2, vaccine development,
and PT-PCR detection. Various AI algorithms are applied for similarity comparisons of gene sequences,
gene fragments, and miRNA prediction [46,164]. In [164], Randhawa et al. used different ML methods to
analyze the pathogen sequences of COVID-19 and identified the inherent features of the viral genomes,
thereby rapidly classifying new pathogens. They collected the complete reference genome of the COVID
virus from NCBI [53], the bat β-coronavirus from GISAID [61], and all available virus sequences from
Virus-Host DB [135]. Each genomic sequence was mapped to a corresponding genomic signal in a
discrete digital sequence by using chaotic game representation [93]. In addition, the amplitude spectrum
of these genomic signals was calculated by using a discrete Fourier transform. On this basis, they used 6
ML classification models to train the above sequence distance matrix and compared their performance.
Finally, they conducted the trained ML models on 29 COVID-19 sequences to classify COVID-19
pathogens. The results of this work support the hypothesis that COVID-19 originated in bats and its
classification as a β-coronavirus.
In [46], Demirci et al. performed a miRNA prediction on the SARS-CoV-2 genome based on 3 ML
methods and identified miRNA-like hairpins and microRNA-mediated SARS-CoV-2 infection
interactions. They collected the complete COVID-19 genome from NCBI [53] and human-mature miRNA
sequences from miRBase [108]. The genomic sequences are transcribed and divided into multiple
overlapping fragments, which are folded into a secondary structure to extract the hairpin structure. On
this basis, the authors used 3 ML methods (e.g., DT, Naive Bayes, and RF) to predict the category of
each hairpin and determined the similarity between the hairpins and human miRNA. They searched for
mature miRNA targets in human and SARS-CoV-2 genes and analyzed the potential interactions
between SARS-CoV-2 miRNAs and human genes and between human miRNAs and SARS-CoV-2 genes.
Finally, the gene ontology of SARS-CoV-2 miRNA targets in human genes were analyzed, and the
similarity between SARS-CoV-2 miRNA candidates and mature miRNAs of any known organism was
evaluated using the PANTHER classification system [134].
In [133], Metsky et al. used genomic and AI technologies to rapidly design nucleic acid detection
assays and improved current RT-PCR testing of SARS-CoV-2. They developed a CRISPR tool that uses
enzymes to edit the genome by cutting specific genetic code chains and used different ML methods to
predict the diversity of the target genome. The authors designed the RT-PCR test method through the
CRISPR tool, and it can effectively detect 67 respiratory viruses, including SARS-CoV-2.
4 Drug and Vaccine Development
Based on proteomics and genomics research, a variety of drug and vaccine development programs have
been proposed for SARS-CoV-2 and COVID-19. The application of AI in the development of new drugs
and vaccines is one of the main contributions in smart medicine and plays an important role in the battle
against COVID-19.
4.1 Drug Development
In the field of drug development, AI technologies can screen existing drug candidates for COVID-19 by
analyzing the interaction between existing drugs and COVID-19 protein targets. In addition, AI
technologies can help to discover new drug-like compounds against COVID-19 by constructing new
molecular structures that have inhibitory effects on proteases at the molecular level. The representative
AI architecture for new drug-like compound discover is shown in Fig. 9.
Drug development can be divided into small-molecule drug discovery and biological product
development. Small-molecule drug discovery mainly focuses on chemically synthesized small molecules of
active substances, which can be made into small-molecule drugs through chemical reactions between
different organic and inorganic compounds. One group of AI-based drug development focuses on the
discovery of new drug-like compounds at the molecular level. In [18,182], Beck et al. proposed a
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Figure 9. Representative AI architecture for new drug-like compound discover.
DL-based drug-target interaction model (MT-DTI) to predict potential drug candidates for COVID-19.
The MT-DTI model uses SMILES strings and amino-acid sequences to predict target proteins with 3D
crystal structures. The authors collected the amino-acid sequences of 3C-like proteases and related
antiviral drugs and drug targets from the databases of NCBI [53], Drug Target Common (DTC) [194],
and BindingDB [120]. In addition, they used a molecular docking and virtual screening tool (AutoDock
Vina [202]) to predict the binding affinity between 3,410 drugs and SARS-CoV-2 3CLpro. The
experimental results provided 6 potential drugs, such as Remdesivir, Atazanavir, Efavirenz, Ritonavir,
Dolutegravir, Kaletra (lopinavir/ritonavir). Note that Remdesivir shows promising in clinical trial.
In [136], Moskal et al. used AI methods to analyze the molecular similarity between anti-COVID-19
drugs (termed “parents”) and drugs involving similar indications to screen out second-generation drugs
(termed “progeny”) for COVID-19. They first used the Mol2Vec [91] method to convert the molecular
structure of the parent drugs into a high-dimensional vector space, treated the drug molecule as a
“sentence”, and mapped its molecular substructure to a “word”. Then, they used the VAE [186] model to
generate SMILES strings with similar 3D shape and pharmacodynamic properties to a given seed
molecule [63]. In addition, CNN, LSTM, and MLP models are used to generate the corresponding
SMILES strings and molecules. The authors selected 71 parent drugs as seed molecules from the
literature and selected 4456 drugs as candidate progeny drugs from ZINC [245] and ChEMBL [56].
In [23], Bung et al. committed to the development of new chemical entities for the SARS-CoV-2
3CLpro based on DL technology. They constructed an RL-based RNN model to classify protease
inhibitor molecules and obtained a smaller subset that favored the chemical space. Then, they collected
2515 protease inhibitor molecules in SMILES format from the ChEMBL database as training data, where
each SMILES string is regarded as a time series, and each position or symbol is regarded as a time point.
The output of small molecules was docked to the 3CLpro structure with minimal energy and ranked
based on the virtual screening score obtained by selecting candidates of anti-SARS-CoV-2 [202]. In [192],
Tang et al. analyzed 3CLpro with a 3D structure similar to SARS-CoV and evaluated it as an attractive
target for anti-COVID-19 drug development. They proposed an advanced deep-Q learning network
(called ADQN-FBDD) to generate potential lead compounds of SARS-CoV-2 3CLpro. They collected
284 reported molecules as SARS-CoV-2 3CLpro inhibitors. These molecules were split using the
improved BRICS algorithm [45] to obtain the target fragment library of SARS-CoV-2 3CLpro. Then, the
proposed ADQN-FBDD model trains each target fragment and predicts the corresponding molecules and
lead compounds. Through the proposed Structure-Based Optimization Policy (SBOP), they finally
obtained 47 derivatives with inhibitory effects on SARS-CoV-2 3CLpro from these lead compounds,
which are regarded as potential anti-SARS-CoV-2 drugs.
Another group of studies focused on screening candidate biological products for COVID-19.
Biological products are a type of protein products with therapeutic effects, which are mainly combined
with specific cell receptors involved in the disease process. Biological products are prepared from
microbial cells such as genetically modified bacteria, yeast, or mammalian cell strains through
biotechnology processes. In [79], Hu et al. established a multitask DL model to predict the possible
binding between potential drugs and SARS-CoV-2 protein targets, thereby selecting available drugs for
SARS-CoV-2. They first collected 8 SARS-CoV-2 viral proteins from GHDDI [58] as potential targets.
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The proposed DL model is based on the AtomNet model [188,205] and includes a shared layer to learn
the joint representation of all tasks and a task processing layer for performing specific tasks. By
fine-tuning the DL model using a coronavirus-specific dataset, the model can predict the possible binding
between the drugs and the protein targets and output the binding affinity score. Based on existing
studies, RdRp, 3CLpro, and papain-like protease have been confirmed as the three principal targets of
SARS-CoV-2 [60,146,206]. Based on the prediction results [113,210], the authors selected the top 10
potential drugs with a high likelihood of inhibition for each target. In [98], Kadioglu et al. used
High-Performance Computing (HPC), virtual drug screening, molecular docking, and ML technologies to
identify SARS-CoV-2 drug candidates. After performing virtual drug screening and molecular docking,
two supervised ML models(e.g., NN and Naivebayes) were used to analyze clinical drugs and test
compounds to construct corresponding drug likelihood prediction models. Several approved drugs,
including those used for the hepatitis C virus (HCV), the enveloped ssRNA virus, and other infectious
diseases, were selected as SARS-CoV-2 drug candidates.
Facing the known COVID-19 protease target 3CLpro, Zhavoronkov et al. [240] designed a
small-molecule drug-discovery pipeline to produce 3CLpro inhibitors, used 3CLpro’s crystal structure,
homology modeling, and co-crystallized fragments to generate 3CLpro molecules. They collected the
crystal structure of COVID-19 3CLpro from [230] and constructed a homology model. At the same time,
molecules with activity on various proteases were extracted from [56,89] and constituted a protease
peptidomimetic dataset with 5,891 compounds. Then, they used 28 ML methods (such as GAE, GAN,
and GA) and RL strategies to separately train input datasets (e.g., crystal structure, homology model,
and co-crystal ligands), and generated new molecular structures with a high score. In [78], Hofmarcher et
al. used a ChemAI DL model [154] based on the SmilesLSTM structure [76] to test the resistance of the
molecules to COVID-19 proteases. They collected 3.6 million molecules from ChEMBL [56], ZINC [245],
and PubChem [104] and formed a training dataset. Then, the ChemAI model was trained on the dataset
in a multitask parallel training way, where the output neurons of the model represent the biological
effects of the input molecules. The authors used the ChemAI model to predict the inhibitory effects of
these molecules on the 3CLpro and PLpro proteases of COVID-19. These molecules have a binding,
inhibitory, and toxic effect on the targets. A list of COVID-19 drug development methods based on AI is
provided in Table 4.
4.2 Vaccine Development
Currently, there are 3 types of COVID-19 vaccine candidates, such as (1) whole virus vaccines, (2)
recombinant protein subunit vaccines, and (3) nucleic acid vaccines [38,238]. AI technology has been
involved in the design and development of COVID-19 vaccines. Compared with explicit applications in
other fields, AI technology is usually used in the sub-processes of vaccine development in an implicit
manner.
The AI algorithms of netMHC and netMHCpan are used in the development of COVID-19 vaccines
for epitope prediction [74,97,215]. In [74], Herst et al. obtained the SARS-CoV-2 protein sequences from
GenBank and used the MSA algorithm to trim the nucleocapsid phosphoprotein sequences to possible
peptide sequences. On this basis, they used netMHC and netMHCpan AI algorithms to train and predict
peptide sequences [8, 97]. The pan variant of netMHC integrates the in-vitro objects of 215 HLAs for
prediction. Finally, they used the average value of the ANN, SVM, netMHC and netMHCpan methods
to calculate the vaccine candidates. In [215], Ward et al downloaded the SARS-CoV-2 nucleotide
sequences from the NCBI [53] and GISAID [61] databases, and generated a consensus sequence for each
SARS-CoV-2 protein. The sequences can be used as references for prediction, specificity, and epitope
mapping analysis. Next, the authors used different epitope prediction tools to predict B cell epitopes and
map them to the amino acid sequences of each gene. On this basis, they used the AI-based netMHCpan
algorithm to predict HLA-1 peptides and obtained a total of 2,915 alleles in all peptide lengths.
BLASTp tool [6] was used to locate the short amino acid epitope sequences to the canonical sequences of
SARS-CoV-2 proteins. Finally, the author provided an online tool that provides functions of
SARS-CoV-2 genetic variation analysis, epitope prediction, coronavirus homology analysis, and
candidate proteome analysis.
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Table 4. Drug development of COVID-19 based on AI methods.
Literature AI methods Role of AI methods COVID-19
targets
Potential
drugs
Tang [192] 1 RL, DQN predict molecules and lead
compounds for each target
fragment
3CLpro 47 compounds
Zhavoronkov [240]
2
28 ML generate new molecular
structures for 3CLpro
3CLpro 100 molecules
Bung [23] RNN, RL classify protease inhibitor
molecules
3CLpro 31 compounds
Hofmarcher [78] 3 ChemAI predict inhibitory effects
of molecules on COVID-19
proteases
3CLpro, PLpro 30,000
molecules
Kadioglu [98] NN, Naive
bayes
construct drug likelihood
prediction model
spike protein, · · · 3 drugs
Hu [79] DL predict binding between
drugs and protein targets
3CLpro, RdRp,
· · ·
10 drugs
Beck [18,182] MT-DTI predict binding affinity be-
tween drugs and protein
targets
3CLpro, RdRp,
helicase, · · ·
6 drugs
Moskal [136] VAE, CNN,
LSTM, MLP
generate SMILES strings
and molecules
- 110 drugs
1
https://github.com/tbwxmu/2019-nCov.
2
https://www.insilico.com/ncov-sprint.
3
https://github.com/ml-jku/sars-cov-inhibitors-chemai.
In [143], Ong et al. used ML and Reverse Vaccinology (RV) methods to predict and evaluate
potential vaccines for COVID-19. They used RV to analyze the bioinformatics of pathogen genomes to
identify promising vaccine candidates. They obtained the SARS-CoV-2 sequences and all proteins of the
6 known human coronavirus strains from the NCBI [53] and UniProt [17] databases. Then, they used
Vaxign and Vaxign-ML [71,142] to analyze the complete proteome of the coronaviruses and predicted
their service biological characteristics. Next, they improved the Vaxign-ML model based on ML and RV
using LR, SVM, KNN, RF, and XGBoost methods and predicted the protein level of all SARS-CoV-2
proteins. The nsp3 protein was selected for phylogenetic analysis, and the immunogenicity of nsp3 was
evaluated by predicting T cell MHC-I and MHC-II and linear B cell epitopes.
In [158], Qiao et al. used DL to predict the patient’s mutated new antigen and identified the best
T-cell epitope for peptide-based COVID-19 vaccines. They first sequenced the diseased cells in the
patient’s blood and extracted 6 human leukocyte antigen (HLA) types and T-cell receptor (TCR)
sequences. Then, they proposed the DeepNovo model to train the patient’s immune peptide and to
identify the best T-cell epitope set based on a person’s HLA alleles and immune peptide group
information. The DeepNovo model uses LSTM and RNN structures to capture sequence patterns in
peptides or proteins and predicts HLA peptides from conserved regions of the virus, thereby predicting
new mutant antigens in patients. In addition, they used the IEDB [204] tool to predict the
immunogenicity of 177 peptides. They suggested designing an epitope-based COVID-19 vaccine
specifically for each person based on their HLA alleles.
The prediction of immune stimulation ability is an important part of vaccine designing [162,166].
Different ML methods and position-specific scoring matrices (PSSM) are usually used to predict epitope
and immune interactions, thereby predicting the generation of adaptive immunity in the target host.
In [162], Rahman et al. used immuno-informatics and comparative genomic methods to design a
multi-epitope peptide vaccine against SARS-CoV-2, which combines the epitopes of S, M, and E proteins.
They used the Ellipro antibody epitope prediction tool [87] to predict linear B cell epitopes on the S
protein. Ellipro uses multiple ML methods to predict and visualize a given protein sequence or B-cell
epitope in the structure. In addition, Sarkar et al. [172] studied the epitope-based vaccine design for
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COVID-19 and used the SVM method to predict the toxicity of the selected epitopes. In [153], Prachar
et al. used 19 epitope-HLA combined prediction tools including IEDB, ANN, and PSSM algorithms to
predict and verify 174 SARS-CoV-2 epitopes.
5 Epidemic and Transmission Prediction
Thanks to the developed information and multimedia technology, the outbreak and spread of COVID-19
were reported in a timely and accurate manner. The number of suspected, confirmed, cured, and dead
COVID-19 cases in each country/region is announced in real time. In addition, passenger travel
trajectories and related big data are shared for scientific research. Based on the rich data, numerous
researchers have participated in the prediction, spread, and tracking of the COVID-19 outbreak.
5.1 Patient Mortality and Survival Rate Prediction
Researchers collected clinical COVID-19 case data and used different AI methods to extract important
features and to predict the mortality and survival rate of patients with COVID-19. The representative
AI architecture for prediction of patient mortality and survival rate is shown in Fig. 10.
Figure 10. Representative AI architecture for prediction of patient mortality and survival rate.
In [152], Pourhomayoun et al. used 6 AI methods to predict the mortality rate of patients with
COVID-19. They used public data of patients with COVID-19 from 76 countries around the world [225],
and counted 112 features, including 80 medical annotations and disease features and 32 features from the
patients’ demographic and physiological data. Based on the filtering method and wrapper method, 42
best features were extracted, such as demographic features, general medical information, and patient
symptoms. On this basis, 6 AI methods (such as SVM, NN, RF, DT, LR, and KNN) are used to predict
the mortality of patients with COVID-19. In [173], Sarkar et al. used the RF model to analyze the
records of 433 patients with COVID-19 from Kaggle [43] and identified the important features and their
impact on mortality. Experimental results show that patients over 62 years of age have a higher risk of
death. In [228,229], Yan et al. analyzed a blood sample dataset of 404 patients with COVID-19 in
Wuhan, China, and used the XGBoost classification method [37] to select three important biomarkers
and to predict individual patient survival rates. Experimental results with an accuracy of 90% indicated
that higher LDH levels seem to play an important role in distinguishing the most critical COVID-19
cases.
5.2 Outbreak and Transmission Prediction
BlueDot [21] and Metabiota [132] are two AI companies that made accurate predictions for the
COVID-19 outbreak. BlueDot collected large-scale heterogeneous data from various sources, such as
news reports, global ticketing data, animal diseases, global infectious disease alerts, and real-time climate
conditions. Then, it used filtering tools to narrow its focus; used various ML and Natural Language
Processing (NLP) techniques to detect, mark, and display the potential risk frequency of COVID-19; and
predicted the outbreak time of transmission. It is worth mentioning that 9 days before the official
16/36
announcement of the COVID-19 outbreak, BlueDot accurately predicted the epidemic of COVID-19 and
cities with a high risk of virus outbreaks. Metabiota collected large-scale data from social and nonsocial
sources (such as biology, socioeconomic, political, and environmental data) and used technologies such as
AI, ML, big data, and NLP to accurately predict the outbreak, spread, and intervention measures of
COVID-19. More AI-based COVID-19 outbreak and transmission prediction methods are shown in Table
5.
Table 5. COVID-19 outbreak and transmission prediction based on AI methods.
Literature Data sources Methods Country/region
Huang [82] Yang [231], WHO [216] CNN, LSTM, MLP, GRU China
Hu [80,81] The Paper [148], WHO [216] MAE, clustering China
Yang [233] Baidu [16] SEIR, LSTM China
Fong [51,52] NHC [139] SVM, PNN China
Ai [3] WHO [54,216] ANFIS, FPA China, USA
Rizk [168] WHO [216] ISACL-MFNN USA, Italy, Spain
Giuliani [62] Italy [144] EMTMGL Italy
Ayyoubzadeh [14] Worldometer [218], Google [201] LR, LSTM Iran
Marini [129,130] Swiss population Enerpol Switzerland
Lai [110] IATA [126], Worldpop [219] ML Global
Punn [155] JHU CSSE [49] SVR, PR, DNN, LSTM,
RNN
Global
Lampos [111] MediaCloud [131], PHE [64],
ECDC [55]
Transfer learning Global
Although the source of the COVID-19 epidemic has not yet been identified, it was first reported in
Wuhan, China. Therefore, the outbreak and spread of COVID-19 in China have received extensive
attention. In [82], Huang et al. used 4 DL models, such as CNN, LSTM, GRU, and MLP to train and
predict the COVID-19 case data from 7 severe epidemic cities in China. The input of these DL models is
the features of the COVID-19 cases, including the number of confirmed cases, cured cases, and deaths.
Based on the input of the previous 5 days, each model can predict the number of COVID-19 cases for
the following few days. The architecture of the COVID-19 outbreak prediction model based on AI
models is shown in Fig. 11.
Figure 11. Architecture of COVID-19 outbreak prediction model based on DL models.
In [80, 81], Hu et al. used AI methods such as MAE and clustering algorithms to predict the number
of confirmed COVID-19 cases in different provinces and cities in China. In addition, they clustered 34
provinces and cities in China into 9 clusters based on the prediction results and further predicted the
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spread of COVID-19 among provinces and cities. In [233], Yang et al. used the SEIR model [101] and
the LSTM model to predict COVID-19 in China. The population migration data and the latest
COVID-19 epidemiological data from Baidu [16] were input into the SEIR model to derive the epidemic
curves. In addition, they used SARS data from 2003 to pretrain the LSTM model to predict COVID-19
for the following few days, in which epidemiological parameters, such as the transmission, incubation,
recovery probability, and the number of deaths, were selected as input features. Both the SEIR and
LSTM models predicted a daily infection peak of 4,000 in the first week of February. In [51, 52], Fong et
al. obtained early COVID-19 epidemiological data from NHC [139]. Then, they used traditional time
series data analysis methods (e.g., ARIMA, Exponential, and Holt-Winters), ML methods (e.g., KR,
SVM, and DT), and AI methods (e.g., PNN) to analyze and predict future outbreaks.
In addition to China, the outbreak and spread of COVID-19 in other countries (including the United
States, Italy, Spain, Iran, and Switzerland) have also received widespread attention. In [3], Ai et al.
proposed an improved ANFIS method [92] to predict the number of COVID-19 cases. The proposed
system connects fuzzy logic and neural networks and uses and enhanced Flower Pollination Algorithm
(FPA) [232] for model parameter optimization and model training. In [168], Rizk et al. proposed an
improved Multi-layer Feed-forward Neural Network (ISACL-MFNN) model, which uses an Internal
Search Algorithm (ISA) to optimize model parameters and uses the CL strategy to enhance the ISA
performance. From the official COVID-19 dataset reported by the WHO [216], data from January 22,
2020, to April 3, 2020, in the United States, Italy, and Spain were collected to train the ISACL-MFNN
model and to predict the confirmed cases within the next 10 days. In [62], Giuliani et al. collected the
number of infected people in Italian provinces [144] and used the EMTMGL model to simulate and
predict the spatial and temporal distribution of COVID-19 infection in Italy. In [14], Ayyoubzadeh used
real-time COVID-19 epidemic data from Google Trends [201] and Worldometer [218] to predict
COVID-19 cases in Iran. They collected daily epidemic data and saved them as a time series data format
and then used the LR and LSTM models to make predictions, thereby obtaining the outbreak and
spread trend of COVID-19 in Iran. In [129,130], Marini et al. developed an agent-based AI platform to
predict the development of COVID-19 in Switzerland. The system accepts the entire Swiss population as
input data to simulate and predict the spread of COVID-19 in Switzerland. It simulates the people’s
daily trajectories by calibrating the micro-census data and effectively predicts the individual contacts
and possible transmission routes.
Many studies have likewise focused on the prediction of the spread of COVID-19 around the world.
They collected a large amount of travel data, mobile phone data, and social media data and used AI
methods to accurately predict the potential transmission range and transmission route of COVID-19.
In [110], Lai et al. collected a large amount of travel and mobile phone data from [219] and constructed
corresponding models to predict the transmission risk of COVID-19 in different countries. On this basis,
they established air travel network models between domestic cities and cities in other countries to predict
risk cities at home and abroad. In [155], Punn et al. used 2 ML models (e.g., SVR [13] and PR [44]) and
3 DL regression models (e.g., DNN, LSTM [66], and RNN) to predict real-time COVID-19 cases.
In [111], Lampos et al. used an automatic crawling tool to obtain daily confirmed COVID-19 case data
and related articles from online media such as MediaCloud [131], Public Health England (PHE) [64], and
European Centre for Disease Prevention and Control (ECDC) [55]. They used the TL strategy to transfer
the COVID-19 model of the country where the disease spread to other countries that are still in the early
stage of the epidemic curve, and thus achieving the target country’s epidemic prediction. In addition,
companies such as Microsoft Bing [20], Google [201], and Baidu [16] have aggregated multiple available
data sources and developed COVID-19 global tracking systems to provide a visual tracking interface.
In addition to AI methods, various methods based on statistics and epidemiology are used to predict
the outbreak and spread of COVID-19. In [70], He et al. collected the highest viral load in the
pharyngeal swabs of 94 patients with confirmed COVID-19. They fitted a generalized additive model
with identity links and smooth spline curves to analyze its overall trend. A gamma distribution was
fitted to the transmission pair data to evaluate the serial interval distribution. The results of statistical
analysis showed that the patients with confirmed COVID-19 reach the peak of virus shedding before or
during symptom onset, and some kinds of transmission may occur before the initial symptoms. In [208],
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Wang et al. determined a set of technical indicators (e.g., number of infection cases in the hospital, daily
infection rate, and daily cured rate) that reflect the infection status of COVID-19. Next, they proposed a
calculation method based on statistical theory to quantify the iconic characteristics of each period and
predict the turning point in the development of the epidemic. In addition, numerous studies based on
the Susceptible-Infected-Recovered (SIR) and SEIR models have studied the spread of COVID-19 from
an epidemiological perspective. Please see [25,119,169,185,195,199,234] for more information.
5.3 Social Control
When COVID-19 appeared, most countries in the world adopted different forms of social control, social
alienation, school closures, and blockade measures to prevent the spread of the epidemic [203]. AI
technologies have been widely used in epidemic control and social management, including individual
temperature detection, video tracking, contact tracking, intelligent robots, etc. Many countries have used
smart devices equipped with AI to detect suspicious persons in public transportation places such as
airports and train stations [40,167]. For example, infrared cameras are used to scan for high
temperatures in a crowd, and different AI methods perform efficient analysis to detect whether an
individual is wearing a mask in real time. In addition, DL-based video tracking technology is used to
detect and track suspicious COVID-19 patients in public places [31]. Moreover, at the entrances and
exits of cities, the identity information of each passing person was collected. Then, AI-based systems are
used to efficiently query the travel history and trajectory of each passing individual to check whether
they are from a region seriously affected by COVID-19 [35,197].
AI technologies are also used in contact tracking of patients with COVID-19 [100]. For each patient
with confirmed COVID-19, personal data such as mobile phone positioning data, consumption records,
and travel records may be integrated to identify the potential transmission trajectory [57]. In addition,
when people are in social isolation, mobile phone positioning and AI frameworks can assist the
government in better understanding the status of individuals [165]. Moreover, intelligent robots are used
to perform site disinfection and product transfer, and mobile phone positioning functions are used to
detect and track the distribution and flow of personnel.
Another group of studies focused on the impact of various social control strategies on the spread of
COVID-19. In [72], Hellewell et al. proposed a random propagation model to analyze the success rate of
different social control approaches to prevent the spread of COVID-19. By quantifying parameters such
as contact tracking and quarantined cases, the proposed model analyzed the maximum number of cases
tracked every week and measured the feasibility of public health work. In [105], Kissler et al. established
a mathematical model to assess the impact of interventions on the prevalence of COVID-19 in the
United States, and intermittent grooming measures were recommended to maintain effective control of
COVID-19. Koo et al. [107] applied the population and personal behavior data of Singapore to the
influenza epidemic simulation model and assessed different social isolation strategies on the dynamic
transmission of COVID-19. Similarly, Chang et al. [28] constructed a simulation model to evaluate the
propagation and control of COVID-19 in Australia. The model analyzes the propagation characteristics
of COVID-19 and the impact of different control strategies on the propagation results.
6 Data and Resources
The implementation and performance improvement of AI greatly depends on the large-scale available
data and resources. Therefore, we compiled available public resources that can be used for COVID-19
disease diagnosis, virology research, drug and vaccine development, and epidemic and transmission
prediction. Three types of data and resources were summarized, including medical images, biological
data, and informatics resources.
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6.1 Medical Images
We collected 17 groups of COVID-19 medical images such as CXR and CT images from individual
researchers and organizations. Among them, the CXR image data set published by Cohen et al. [41] is
widely cited, which is a collection of CXR images from multiple references. In addition, many researchers
uploaded CXR and CT images to Kaggle [15,112,124,138,160] for COVID-19 research. Moreover,
organizations such as the British Society of Thoracic Imaging (BSTI), Eurorad, and Radiopaedia also
released online CXR and CT images. Table 6 displays the detailed description of medical image data
resources of COVID-19.
Table 6. Medical image data resources for COVID-19 research.
Data sources Data type Cited by Refs.
Zhao [239] CT images [239]
HRCT [48] CT images [94]
Armato [11] CT images [94]
Coronacases [42] CT images -
Medical segmentation [175] CT images -
Cohen [41] CXR images [2, 9, 73,121,127,137,178,209,237]
Wang [213] CXR images [237,239]
COVIDx [24] CXR images [209]
Adrian [159] CXR images [73]
COVID-Net [209] CXR images [209]
Kermany [102] CXR images [9]
Mendeley data [5] CXR images -
Kaggle [15,112,124,138,160] CXR and CT images [2, 9, 121,127,137,173,178,209]
BSTI [140] CXR and CT images [127]
SIRM [184] CXR and CT images -
Eurorad [50] CXR and CT images -
Radiopaedia [161] CXR and CT images -
6.2 Biological Data
We collected 10 biological data resources, such as NCBI, Protein Data Bank (PDB), UniProt, Clarivate
Analytics Integrity (CAI), Drug Target Common (DTC), and Virus-Host DB (VHDB), as shown in
Table 7. These data resources provide abundant biological data resources, including gene sequences,
proteins, drug molecules and compounds, and miRNA sequences.
6.3 Informatics Resources
Informatics resources such as COVID-19 situation reports, dashboards, COVID-19 cases, and
demographic data are gathered in Table 8. Among them, the World Health Organization (WHO), the
National Health Commission of the People’s Republic of China (NHC), the Disease Control and
Prevention (CDC) provided real-time COVID-19 reports. Companies such as Baidu, Microsoft Bing,
Google, and JHU CSSE provided online dashboards for COVID-19 spread tracking. Organizations such
as Govuk, Il Sole, and ECDC provided real-time COVID-19 cases in the UK, Italy, and Europe.
7 Challenges and Future Directions
Although AI technologies have been used in fighting against COVID-19, and many studies have been
published, we note that the applications and contributions of AI in this work are still relatively limited.
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Table 7. Biological data sources for COVID-19 research.
Data sources Data type Description Cited by Refs.
NCBI [53] Genome sequences Genome sequencing data of SARS-CoV-2 [18, 46, 143,
164,182]
GISAID [61] Genome sequences Bat Betacoronavirus RaTG13 [164]
VHDB [135] Genome sequences Virus sequences [164]
PDB [149] Proteins 3D shapes of proteins, nucleic acids, and
assemblies
[19, 145]
UniProt [17] Proteins SARS-CoV-2 protein entries and receptors [143]
miRBase [108] miRNA sequences Human mature miRNA sequences [46]
ZINC [245] Drug compounds drug compounds and molecules [78,98,136]
DTC [194] Drug molecules Drug molecules for 3C-like proteases [18,182]
CAI [89] Drug discovery Empowering knowledge-based drug discov-
ery and development
[240]
BindingDB [120] Amino-acid sequences Amino-acid sequences of 3C-like proteases [18,182]
Table 8. Informatics resources for COVID-19 research.
Data sources Data type Description Cited by Refs.
WHO [216] Report COVID-2019 situation reports [3, 80,82,168]
NHC [139] Report Real-time COVID-19 Report [51,52]
CDC [54] Report Weekly U.S. influenza surveillance report [3, 111]
GitHub [88] Code Codes and datasets for COVID-19 study [24,58,239]
Baidu [16] Dashboard Dashboard for COVID-19 tracking [233]
Bing [20] Dashboard Dashboard for COVID-19 tracking -
Google [201] Dashboard Dashboard for COVID-19 tracking [14]
JHU CSSE [49] Dashboard Dashboard for COVID-19 tracking [155]
Worldometer [218] COVID-19 cases COVID-19 pandemic cases [14]
Govuk [64] COVID-19 cases COVID-19 cases in the UK [111]
ECDC [55] COVID-19 cases COVID-19 cases worldwide [111]
Il Sole [144] COVID-19 cases COVID-19 datasets in Italy [62]
Worldpop [219] Demographic data Spatial demographic and air travel data [110]
GHDDI [58] Community Drug discovery community [79]
Humdata [68] Community community perceptions of COVID-19 -
We summarize the main challenges currently faced by AI against COVID-19 and provide the
corresponding suggestions.
7.1 Challenges
At present, the applications of AI in COVID-19 research mainly faces four challenges: the lack of
available large-scale training data, massive noisy data and rumors, the limited knowledge on the
intersection of computer science and medicine, and data privacy and human rights protection.
• Lack of available large-scale training data. Most AI methods rely on large-scale annotated training
data, including medical images and various biological data. However, due to the rapid outbreak of
COVID-19, there are insufficient datasets available for AI. In addition, annotating training samples
is very time-consuming and requires professional medical personnel.
• Massive noisy data and rumors. Challenges arise from relying on the developed mobile Internet
and social media; massive noise information and fake news about COVID-19 has been published on
various online media without rigorous review. However, AI algorithms seem to be powerless in
21/36
judging and filtering the noise and erroneous data. This problem limits the application and
performance of AI, especially in epidemic prediction and transmission analysis.
• Limited knowledge in the intersection of computer science and medicine. Many AI scientists are
from computer science, but the application of AI in the COVID-19 battle requires in-depth
cooperation in computer science, medical imaging, bioinformatics, virology, and many other
disciplines. Therefore, it is crucial to coordinate the cooperative work of researchers from different
fields and integrate the knowledge of multiple subjects to jointly deal with COVID-19.
• Data privacy and human rights protection. In the era of big data and AI, the cost of obtaining
personal privacy data is very low. Faced with public health issues such as COVID-19, many
governments want to obtain various types of personal information, including mobile phone
positioning data, personal travel trajectory data, and patient disease data. How to effectively
protect personal privacy and human rights during information acquisition and AI-based processing
is an issue worthy of discussion and attention.
7.2 Future Directions
In addition to the applications investigated in this paper, AI can also contribute to the battle of
COVID-19 from the following 10 potential directions.
1. Noncontact disease detection. In CXR and CT image detection, the use of noncontact automatic
image acquisition can effectively avoid the risk of infection between radiologists and patients during
the COVID-19 pandemic. AI can be used for patient posture positioning, standard section
acquisition of CXR and CT images, and movement of camera equipment.
2. Remote video diagnosis. AI and NLP technologies can be used to develop remote video diagnosis
systems and chat robot systems and provide COVID-19 disease consultation and preliminary
diagnosis to the public.
3. Patient prognosis management. AI technology (such as intelligent image and video analysis) can be
used to automatically monitor patient behavior during the follow-up monitoring and prognostic
management process, in addition to long-term tracking and management of patients with
COVID-19.
4. Biological research. In the field of biological research, AI can be used to discover protein structures
and features of virus through accurate analysis of biomedical information, such as large-scale
protein structures, gene sequences, and viral trajectories.
5. Drug and vaccine development. AI can not only be used to discover potential drugs and vaccines
but also to simulate the interaction between drugs and proteins and between vaccines and
receptors, thereby predicting the potential responses to the drugs and vaccines of patients with
COVID-19 with different constitutions.
6. Identification and filtering of fake news. AI can be used to reduce and eliminate fake news and
noise data on online social media platforms to provide reliable, correct, and scientific information
about the COVID-19 pandemic.
7. Impact simulation and evaluation. Various simulation models can use AI to analyze the impact of
different social control strategies on disease transmission. Then, they can be used to explore more
effective and scientific approaches of disease prevention and social control.
8. Patient contact tracking. By constructing social relationship networks and knowledge graphs, AI
can identify and track the trajectories of people in close contact with patients with COVID-19,
thereby accurately predicting and controlling the potential spread of the disease.
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9. Intelligent robots. Intelligent robots are expected to be used in applications such as disinfection
and cleaning in public places, product distribution, and patient care.
10. Intelligent Internet of Things. AI is expected to be combined with the Internet of Things to deploy
in customs, airports, railway stations, bus stations, and business centers. In this case, we can
quickly identify suspicious COVID-19 virus and patients through intelligent monitoring of the
environment and personnel.
8 Conclusions
In this survey, we investigated the main scope and contributions of AI in combating COVID-19.
Compared with the pandemic of SARS-CoV in 2003 and MERS-CoV in 2012, AI technologies have been
successfully applied in almost every corner of the COVID-19 battle. The application of AI in COVID-19
research can be summarized in four aspects, such as disease detection and diagnosis, virology research,
drug and vaccine development, and epidemic and transmission prediction. Among them, medical image
analysis, drug discovery, and epidemic prediction are the main battlefields of AI in the fight against
COVID-19. We also summarized the currently available data and resources for COVID-19 research based
on AI, including medical imaging data, biological data, and informatics resources. Finally, we highlighted
the main challenges and potential directions in this field. This survey provided medical and AI
researchers with a comprehensive view of the existing and potential contributions of AI in combating
COVID-19, with the goal of inspiring them to continue to maximize the advantages of AI and big data
to fight against this pandemic.
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